|
|
Hopen Life Sciences was formed in 2006 to take advantage of converging market dynamics in the life science field in the region. The team consists of experienced professionals with diverse life science backgrounds in research and development, business development, operations, marketing, clinical trials, finance, and patient care. To date, Hopen has leveraged its network of life science expertise as well as financial capital to invest in a portfolio of early- to mid-stage companies that includes diagnostics, therapeutics, medical devices, and enabling technologies. Hopen seeks to invest $3 to $5 million over the life of the investment, but have the flexibility to do more or less. Hopen Fund I has invested in seven companies including one exit through a combination of initial and follow-on investments. All six of the remaining invested assets continue to progress and have raised, in combination with its syndicated partners, a total of $115 million toward continued creation of investor value. In 2010, the Hopen leadership team decided to expand its investment pool to create a new Life Science venture fund, Hopen Fund II. Through this fund, Hopen will continue to build upon our fundamental approach to investing in leading edge life science opportunities. In July 2011, Hopen announced an initial close of $25 million for its second fund. Currently, Hopen manages over $65 million between the two funds.
|
